Home > Newsletters > FDAnews Drug Daily Bulletin > FDA Pushes Back Review of Two Novo Nordisk Diabetes Candidates
FDAnews Drug Daily Bulletin
June 20, 2012 | Vol. 9 No. 121
FDA Pushes Back Review of Two Novo Nordisk Diabetes Candidates
Novo Nordisk will have to wait until late October to get word on the fate of two ultra-long-acting insulin treatments because the FDA needs additional time to review data clarifications and analyses it requested after the initial NDA submissions. The Danish drugmaker submitted a “substantial” amount of new data, and due to the size and timing of the submissions the agency considers them major amendments to the marketing applications, Novo Nordisk said.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.